Thanks to know-how and inventor’s team, Occlugel has developed a new degradable drug delivery system (DDDS). These innovative and disruptive DDDS allow a swift access to market with a high potential for differentiation. They could offer safety for physicians, ease to patients and are in the respect of the willingness from medical insurance. These DDDS degrade and release locally from a few days to a few weeks different drugs such as antibiotics or pain killer. They are easy to inject in per or post-operative procedure.
Over the years, Occlugel not only has created and developed the first calibrated and degradable microspheres for embolization and chemoembolization in the world but also transferred it successfully to an US industrial. Occlugel has also been rewarded with two “Seal of excellence” for its work on microsphere with double visibility (X-rays and MRI) and in situ drug delivery.
Occlugel owns a genuine expertise in process transferring to industrial and is looking for long-standing relationships to develop its new DDDS.